<DOC>
	<DOCNO>NCT01818024</DOCNO>
	<brief_summary>This 3 part study investigate safety , tolerability , pharmacokinetics pharmacodynamics single repeat dos GSK2862277 administer via inhalation ( IH ) intravenous ( IV ) rout healthy subject . Part 1 study involve initial assessment safety , tolerability pharmacokinetics GSK286227 , via single escalate intravenous dos , compare predecessor molecule , GSK1995057 . After completion Part 1 interim data review occur ass key comparability criterion inform progression Part 2 study . Part 2 study involve single dose GSK2862277 level predict close therapeutic dose level . Part 2 investigate intravenous inhale route administration , sequential manner , respectively . An interim data review also occur completion Part 2 , data accumulate previously assess examine appropriateness progress Part 3 . Part 3 study involve 5 day repeat dose via inhale intravenous route use dose administer Part 2 .</brief_summary>
	<brief_title>A Study Investigate Safety Tolerability Pharmacokinetics , Pharmacodynamics Inhaled Intravenous GSK2862277 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>Male female 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subject positive screening HAVH autoantibody GSK1995057 ( Part 1 ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Exposure four new chemical entity within 12 month prior first dose day . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Exposure four new chemical entity within 12 month prior first dose day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>TNFR1</keyword>
	<keyword>domain antibody</keyword>
	<keyword>Lung injury</keyword>
</DOC>